Studies on the use of Hydroxychloroquin for the treatment of COVID-19
Posted: Wed Apr 15, 2020 7:02 pm
Ncbi general search
https://www.ncbi.nlm.nih.gov/pmc/?term= ... e%22+covid
"Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102587/
"Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/
"The results of this clinical trial confirmed the short-term efficacy of HCQ in the treatment of COVID-19, which can effectively improve lung imaging findings, promote a virus-negative conversion, and shorten the disease course"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102614/
"All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151271/
"This strategy for prevention is clearly achievable considering the safety of hydroxychloroquine for a short period of time, its demonstrated antiviral effect and its low cost and accessibility."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128742/
https://www.ncbi.nlm.nih.gov/pmc/?term= ... e%22+covid
"Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102587/
"Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/
"The results of this clinical trial confirmed the short-term efficacy of HCQ in the treatment of COVID-19, which can effectively improve lung imaging findings, promote a virus-negative conversion, and shorten the disease course"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102614/
"All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151271/
"This strategy for prevention is clearly achievable considering the safety of hydroxychloroquine for a short period of time, its demonstrated antiviral effect and its low cost and accessibility."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128742/